title: [A six-month intravenous repeated dose toxicity study of tazobactam/piperacillin and tazobactam in dogs].
abstract: Tazobactam (TAZ) is a newly developed beta-lactamase inhibitor. Tazobactam/Piperacillin (TAZ/PIPC) is a formulation consisting of TAZ and PIPC in a ratio of 1:4. A six-month intravenous repeated dose toxicity study of TAZ/PIPC and TAZ including a one-month recovery period were carried out using male and female dogs. The doses were 200, 400 and 800 mg/kg/day for TAZ/PIPC, and 40, 80 and 160 mg/kg/day for TAZ. The results were as follows. 1. No test article-related deaths occurred during the study period. No effects on clinical findings, body weight and food consumption were evident. 2. No test article-related changes were noted in hematological, serum biochemical and urinalysis evaluations, and opthalmological and electrocardiographic examinations. 3. There were no test article-related changes in macroscopic findings or organ weight. 4. The histopathological examination revealed deposition of marked PAS-positive aggregates in liver cells of dogs given 400 mg/kg/day or more of TAZ/PIPC and 80 mg/kg/day or more of TAZ. Electron micrographs of hepatocytes revealed glycogen granules to be accumulated in the cytoplasm, and an increase of smooth endoplasmic reticulum. 5. After a one-month recovery period, the histopathological changes had generally disappeared, suggesting that they were reversible. 6. From the histopathological changes of liver, the no-toxic dose levels for TAZ/PIPC and TAZ were 200 mg/kg/day and 40 mg/kg/day, respectively.
authors: Drug Safety Laboratory, Taiho Pharmaceutical Co., Ltd., Tokushima, Japan.
authors: T
authors: T
authors: Hayashi
authors: H
authors: H
authors: Yada
authors: M
authors: M
authors: Blair
authors: K A
authors: KA
authors: Laughlin
authors: G L
authors: GL
authors: Blanchard
authors: P C
authors: PC
authors: Tucek
authors: R G
authors: RG
authors: Geil
mesh_terms: D000818:Animals; D004285:Dogs; D004359:Drug Therapy, Combination / Q000633:toxicity*; D005260:Female; D007275:Injections, Intravenous; D008297:Male; D010397:Penicillanic Acid / Q000031:analogs & derivatives* / Q000633:toxicity; D010878:Piperacillin / Q000633:toxicity*; D000078142:Tazobactam; D065093:beta-Lactamase Inhibitors
chemical_list: D065093:beta-Lactamase Inhibitors; D010397:Penicillanic Acid; D000078142:Tazobactam; D010878:Piperacillin